Vir Biotechnology (VIR) Expected to Post Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is expected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.3336 per share and revenue of $135.8820 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.84). The company had revenue of ($0.03) million for the quarter, compared to analysts’ expectations of $55.49 million. Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.During the same quarter in the previous year, the business posted ($0.88) EPS. On average, analysts expect Vir Biotechnology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vir Biotechnology Stock Performance

NASDAQ VIR opened at $8.66 on Monday. The stock’s fifty day moving average is $9.33 and its two-hundred day moving average is $8.97. The firm has a market capitalization of $1.46 billion, a P/E ratio of -2.77 and a beta of 1.66. Vir Biotechnology has a fifty-two week low of $4.16 and a fifty-two week high of $11.66.

Insider Activity

In related news, Director Janet Napolitano sold 3,200 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total value of $30,240.00. Following the sale, the director directly owned 21,216 shares in the company, valued at approximately $200,491.20. The trade was a 13.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cinctive Capital Management LP increased its holdings in Vir Biotechnology by 14.8% in the 4th quarter. Cinctive Capital Management LP now owns 27,755 shares of the company’s stock valued at $167,000 after purchasing an additional 3,572 shares during the last quarter. Captrust Financial Advisors lifted its stake in Vir Biotechnology by 39.7% during the second quarter. Captrust Financial Advisors now owns 30,739 shares of the company’s stock worth $155,000 after purchasing an additional 8,739 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Vir Biotechnology during the fourth quarter worth $136,000. Focus Partners Wealth grew its stake in shares of Vir Biotechnology by 15.3% in the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after buying an additional 2,566 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Vir Biotechnology by 87.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,146 shares of the company’s stock valued at $109,000 after buying an additional 8,906 shares during the period. 65.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on VIR. Morgan Stanley boosted their price target on shares of Vir Biotechnology from $23.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, June 11th. Leerink Partners raised their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Finally, Wall Street Zen lowered shares of Vir Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Vir Biotechnology has an average rating of “Moderate Buy” and an average price target of $20.88.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.